A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate safety, tolerability and preliminary efficacy of
SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced
solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination
therapy for HER2-expressing advanced malignant tumors of patients.